louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06511635: Multicenter Quantitative and Qualitative Study of the Determinants of Participation in a Cytomegalovirus Preventive Vaccine Study in France in Women Aged 18 to 40 Years Old.
Official title: Multicenter Quantitative and Qualitative Study of the Determinants of Participation in a Cytomegalovirus Preventive Vaccine Study in France in Women Aged 18 to 40 Years Old.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Recruitment
Keywords: Recruitment methods
Determinants
CMVCTORY vaccine trial
women's participation
vaccine trial
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 306
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All french participants of the CMVCTORY vaccine trial.

Brief summary: During a vaccine clinical trial of Cytomegalovirus (CMV) vaccine, one of the participants' motivations was to prevent an infection responsible for malformations in a future child. Would their attitude towards a vaccine trial be the same in the context of a vaccine designed to protect them individually? By improving the knowledge of clinical research and determinants in women aged 18 to 40, this study could improve recruitment methods in this specific population for future vaccine trials within the CIC1408 infectious diseases and vaccinology area at Saint-Etienne University Hospital.


Eligibility criteria: Inclusion Criteria:

* Womens between 18 to 40 included in CMVCTORY vaccine trial

Exclusion Criteria:

* Refusal

Primary outcomes:
measure: qualitative interview
timeFrame: Day : 1
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: Centre Hospitalier Universitaire de St Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Nelly JACQUEMET, nurse
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00591435: Influence of Resident Training on Intra-operative Workflow
Official title: Resident Training Affects Intra-Operative Workflow and Costs
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intraoperative Workflow
Anesthesia and Procedure Related Time Intervals
Keywords: Anesthesia
Surgery
Education
Economics
Lead sponsor: University Hospital Schleswig-Holstein
Sponsor class: OTHER
Collaborators: name: Department of Anaesthesiology and Intensive Care Medicine
First posted: 2008-01-11
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy subjects scheduled for one of the three defined procedures (defined by German Diagnose Related Groups ID) under general or regional anesthesia

Brief summary: Anaesthesia and surgery related time intervals of three standard operations are compared depending on whether residents or consultants are performing anaesthesia and surgery.

Hypothesis: Perioperative workflow is influenced by state of education, time intervals reflecting anaesthesia as well as surgical performance increase due to resident training. Therefore, costs of perioperative care increase as well.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects scheduled for one of the three defined procedures (defined by German Diagnose Related Groups ID) under general or regional anesthesia

Exclusion Criteria:

* Patient's refusal of data collection, emergency procedures, change of physician in charge (resident to consultant or the other way around) of anesthesia or surgical team

Primary outcomes:
measure: Anaesthesia and procedural related time intervals
timeFrame: All events will be recorded intraoperativly
Secondary outcomes:
measure: OR costs are calculated as $ 15.00 per minute, additional costs due to increase of time intervals will be analyzed
timeFrame: All data will be recorded intraoperaitvly
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: University Hospital Schleswig-Holstein, Campus Kiel
state: Schleswig-Holstein
Study officials:
affiliation: Department of Anaesthesiology and Intenisve Care Medicine, University Hospital Schleswig-Holstein, Campus Kiel
name: Jens Scholz, MD, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06355635: Application and Monitoring of Vasoactive and Inotrope Drugs
Official title: Evaluation of Application and Monitoring of Vasoactive and Inotrope Drugs in Non-cardiac Surgery Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hemodynamic Instability
Lead sponsor: Johannes Gutenberg University Mainz
Sponsor class: OTHER
First posted: 2024-04-09
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All Anesthesiologists

Brief summary: The investigators aimed to establish current practice of application and monitoring of vasoactive and inotrope Drugs in non-cardiac surgery patients.

Detailed description: This survey provides a current update on a variety of cardioactive and vasoactive drugs at non-cardiac surgery patients in germany.

Eligibility criteria: Inclusion Criteria:

* all anesthesiologists of germany

Exclusion Criteria:

* not completely responses

Primary outcomes:
measure: current practice of correct application and monitoring of vasoactive and inotrope Drugs
timeFrame: through study completion, an average of 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Mainz
country: Germany
facility: Department of Anaesthesiology;
state: Rhineland-Palatinate
Study officials:
affiliation: University Medical Centre
name: Marc Kriege
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05807958: Allergy Testing of Soldiers Prepared for International Mission
Official title: Validation of the Benefit of Allergy Testing of Soldiers Prepared for International Mission with Specific Allergen Panels
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adult Military Personnel
Lead sponsor: Queen Astrid Military Hospital
Sponsor class: OTHER
First posted: 2023-04-11
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this prospective mono centric study is to identify relevant commercially available allergen extracts for allergy testing in soldiers prepared for international mission.

Participants will receive a skin prick test with the skin prick automated test device including 22 allergens and 2 controls on both forearms.


Eligibility criteria: Inclusion Criteria:

* Adult military personnel (18-65y) will be included. Soldiers with and without previous exposure to allergens in the regions of interest will be included. Soldiers who are performing desk tasks and not selected for international missions will serve as controls.

Exclusion Criteria:

* Skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment
* Use of antihistaminic medication \< 7 days before the start of the study
* Use of tricyclic antidepressants (antihistamine activity) \< 7 days before the start of the study
* Use of topical corticoids on the forearm \< 7 days before the start of the study
* Use of Omalizumab \< 6 months before the start of the study
* Pregnancy: there is a remote possibility of inducing a systemic allergic reaction that could induce uterine contractions or necessitate the use of epinephrine (thought to cause constriction of the umbilical artery).

Primary outcomes:
measure: Allergens with positive skin reaction
timeFrame: baseline
Secondary outcomes:
measure: Self-reported allergic diseases
timeFrame: baseline
measure: Work Performance & Activity Impairment
timeFrame: baseline
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Military Hospital Queen Astrid
Study officials:
affiliation: Military Hospital Queen Astrid
name: Ilan Baron, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gorris S, Uyttebroek S, Backaert W, Jorissen M, Schrijvers R, Thompson MJ, Loeckx D, Seys SF, Van Gerven L, Hellings PW. Reduced intra-subject variability of an automated skin prick test device compared to a manual test. Allergy. 2023 May;78(5):1366-1368. doi: 10.1111/all.15619. Epub 2022 Dec 26. No abstract available.
Clinical trial NCT04532658: Evaluation of Coaching Impact on Surgical Outcomes
Official title: Understanding the Influence of Human and Organizational Factors on Surgeon Performance to Enhance Patient Outcomes: Experimental Evaluation of a Customized Coaching Program
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Surgery
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-08-31
Enrollment: 16000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This two arms parallel cluster-randomized trial will evaluate the impact of a customized coaching program for surgeons on the occurrence of patient major adverse events. Trends in surgical outcomes before and after the intervention will be compared between surgeons randomly assigned to the coaching program against non-exposed surgeons.


Eligibility criteria: Inclusion Criteria:

* All adults needing a surgery who are operated by one of the participating surgeons

Exclusion Criteria:

* Age \< 18 years old
* Absence of surgical procedure
* Palliative care
* Organ transplantation
* Refusal for personal data sharing

Primary outcomes:
measure: Occurrence of major adverse event
timeFrame: During surgery or within 30 days after the operation
measure: Occurrence of death
timeFrame: During surgery or within 30 days after the operation
measure: Occurrence of unplanned stay in critical/intensive care unit
timeFrame: Within 30 days after the operation
measure: Occurrence of unplanned reoperation
timeFrame: Within 30 days after the operation
measure: Occurrence of intraoperative and postoperative complications
timeFrame: During surgery or within 30 days after the operation
measure: : Occurrence of avoidable hospital readmission for complication
timeFrame: Within 30 days after the operation
measure: Operative time
timeFrame: From skin incision to wound closure
measure: Length of stay
timeFrame: From hospital admission to discharge, within 30 days after operation
measure: Hospitalization costs
timeFrame: Within 30 days after the operation
measure: Surgeon well-being
timeFrame: Throughout the study, Through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
References:
Clinical trial NCT05520658: Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts
Official title: Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Plantar Wart
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2022-08-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Warts are common skin infections caused by human papillomavirus (HPV), which can cause a variety of skin presentations according to its type, site and the immune status .Nongenital warts may be presented as common, plane, plantar, filiform, or mucosal warts .Most people are affected by cutaneous warts, either plantar warts or common warts .prevalence of skin warts is between 3% and 13% and plantar warts are about 30% of skin warts in western world .Majority of cases occur in adolescent and young adults


Eligibility criteria: Inclusion Criteria:

* Age:\>18 years .
* Sex: both males and females will be included.
* Confirmed diagnosis by clinical and dermoscopic examination of plantar warts will be made

Exclusion Criteria:

* Patients with history or evidenced hypersensitivity to any component used in this study.
* Pregnancy \& lactating.
* Patients who receive immune suppressive therapy.
* Patients who receive any wart treatment during the last 2 months before enrollment in the study.
* Patients with systemic illness especially cardiac patients.
* Patients who refused participation in the study

Primary outcomes:
measure: the change in size of plantar wart
timeFrame: 3 month
measure: the change in number of plantar warts
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
citation: Abeck D, Tetsch L, Luftl M, Biedermann T. Extragenital cutaneous warts - clinical presentation, diagnosis and treatment. J Dtsch Dermatol Ges. 2019 Jun;17(6):613-634. doi: 10.1111/ddg.13878.
citation: Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011 Aug;165(2):233-46. doi: 10.1111/j.1365-2133.2011.10218.x. Epub 2011 May 26.
Clinical trial NCT02395458: Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens
Official title: Efficacy on Helicobacter Pylori Eradication With Sequential Antibiotic Compared to Triple Therapy for 14 Days
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Helicobacter Infections
Keywords: Sequential therapy
Triple therapy
Eradication
Lead sponsor: Coordinación de Investigación en Salud, Mexico
Sponsor class: OTHER_GOV
First posted: 2015-03-23
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical trial to compare efficacy on eradicating Helicobacter pylori with two antibiotic strategies: sequential with amoxicillin and omeprazole 5 days and clarithromycin with metronidazole and omeprazole 5 days or omeprazole with clarithromycin and amoxicillin 14 days.

Detailed description: In patients with documented infection with Helicobacter pylori after endoscopy and biopsy, two modalities of treatment were compared, and after a control endoscopy and biopsy, eradication was assessed as well as side effects of both treatments.

Eligibility criteria: Inclusion Criteria:

* Helicobacter pylori infection in biopsy
* Eradication required

Exclusion Criteria:

* Antibiotic received two weeks prior
* Previous treatment for H pylori infection
* Allergy to any of the treatment drugs
* Smoking \> 5 cigarettes daily.

Primary outcomes:
measure: Eradication
timeFrame: 6 to 8 week after treatment
Secondary outcomes:
measure: Side effects
timeFrame: two weeks after beginning of treatment
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01688258: New Multiplex Real-time PCR for Genital Ulcer Disease
Official title: A Prospective, Open Labeled, Multicenter, Diagnostic Study on the Detection of T. Pallidum, H. Ducreyi and HSV Type 1 and 2 From Genital, Anal and Oropharyngeal Ulcers With a New Multiplex Real-time Polymerase Chain Reaction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Genital Ulcer Disease (GUD)
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2012-09-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with genital, anal or oropharyngeal ulcers

Brief summary: (i) To compare a new diagnostic PCR with established diagnostic procedures for T. pallidum (serology, dark field microscopy), H. ducreyi (cultivation), HSV types 1 and 2 (cultivation, PCR).

(ii) To assess the frequency of infections with T. pallidum, H. ducreyi and HSV types 1 and 2 in patients with genital, anal and oropharyngeal ulcers by a new PCR.


Eligibility criteria: Inclusion criteria:

* Patient with genital, anal or oropharyngeal ulcers
* Age minimum of 18 years.
* Informed consent must be obtained from each patient/control patient in written form prior to any study procedure.

Exclusion criteria:

* Antibiotic therapy within 2 weeks before the visit

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Division of Dermatology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Division of Dermatology
name: Philipp Bosshard, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Glatz M, Juricevic N, Altwegg M, Bruisten S, Komericki P, Lautenschlager S, Weber R, Bosshard PP. A multicenter prospective trial to asses a new real-time polymerase chain reaction for detection of Treponema pallidum, herpes simplex-1/2 and Haemophilus ducreyi in genital, anal and oropharyngeal ulcers. Clin Microbiol Infect. 2014 Dec;20(12):O1020-7. doi: 10.1111/1469-0691.12710. Epub 2014 Jul 25.
Clinical trial NCT04965558: Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
Official title: Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Clinical Features and Outcome
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-07-16
Enrollment: 1000
Sex: ALL
Minimum age (years): 6
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with wilson disease

Brief summary: The investigators aimed to observe the clinical features and outcome in patients with osseomuscular type of Wilson's disease from a large cohort during long-term follow-up


Eligibility criteria: Inclusion Criteria:

* genetically diagnosed WD patients

Exclusion Criteria:

* Deny follow-up

Primary outcomes:
measure: Serum ceruloplasmin
timeFrame: From 2004 through 2030
measure: Urinary Copper Excretion
timeFrame: From 2004 through 2030
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Second Affiliated Hospital, Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT04387058: Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Official title: Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cirrhosis Portal
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2020-05-13
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Decompensated cirrhosis is associated with sarcopenia. TIPS is an efficient treatment of portal hypertension. Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes or pre-diabetes. The main objective is to measure the cumulative incidence of diabetes and pre-diabetes 6 months after TIPS insertion.

Detailed description: Based on our retrospective data, we expect that one-third of cirrhotic patients develop glucose dysregulation after TIPS. A better knowledge of the metabolic disorders related to the TIPS could allow to prevent the deleterious effects of the TIPS on the disease (decrease of the insulin-sensitivity, fat gain ...), by simple interventions on diet or physical activity. We will assess the incidence of diabetes and pre-diabetes, and the influence of TIPS on nutritional status and sarcopenia. Patients will be follow-up 6 months after TIPS. We will explore the hormonal mechanisms that explain these changes.

Eligibility criteria: Inclusion Criteria:

* patient cirrhosis and portal hypertension justifying a treatment with TIPS
* written consent.

Exclusion Criteria:

* contraindication for TIPS
* indications of TIPS in emergency or as part of the preparation for a surgical procedure,
* hepatocellular carcinoma outside Milan criteria or cancer at a palliative stage,
* a contra-indication to the realization of an OGTT,
* a hyperglycemic treatment (corticosteroids, somatostatin, etc.),
* hemoglobin \<7 g / dl,
* patients who have had a liver transplant,
* those for whom the follow-up is considered impossible or the vital prognosis is engaged in the short term,
* pregnant or lactating women,
* those unable to receive enlightened information,
* those participating in interventional research
* and finally the persons placed under safeguard of justice, tutelage or curatorship.

Primary outcomes:
measure: the cumulative incidence
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Toulouse
country: France
facility: CHU de Toulouse
state: Haute-garonne
Study officials:
affiliation: University Hospital, Toulouse
name: Maeva GUILLAUME
role: PRINCIPAL_INVESTIGATOR
References: